Is Tirzepatide Easier on the Eyes Than GLP-1s?
Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients with type 2 diabetes than using GLP-1 receptor agonists, a study finds. Medscape Medical News
China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer
US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma’s unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, […]
Semaglutide helps manage metabolic side effects of antipsychotic drugs
Recent clinical research indicates that semaglutide may effectively reverse weight gain and blood sugar issues caused by certain antipsychotic medications. A randomized trial demonstrated that patients taking this drug experienced weight loss and improved metabolic health compared to those receiving a placebo. These findings were published in JAMA Psychiatry. People diagnosed with schizophrenia face a […]
The Ozempic Era Even Comes for adidas’ Post-Samba Sneakers
Another day, another delightfully slim adidas sneaker remade in the Samba’s image. Who’s complaining? The adidas Handball Spezial Lo Pro Core shoe takes a delightfully slim silhouette and makes it even skinnier. The GLP-1-ification of footwear continues. Like other members of adidas’ slim sneaker lineage, the Handball Spezial Lo Pro Core sneaker wears a low-profile […]
Pfizer adds heft to obesity pipeline in $2B Yaopharma deal
A month after besting rival Novo Nordisk A/S in a bidding war for obesity drug developer Metsera Inc., Pfizer Inc. is again adding to its GLP-1 arsenal, this time via a $2 billion licensing and collaboration agreement with Yaopharma, a subsidiary of China’s Fosun Pharmaceutical Co. Ltd.
Eli Lilly to make GLP-1 pill in US
CNN’s Erin Burnett speaks to Eli Lilly CEO David Ricks on major changes to weight-loss drugs and expanded manufacturing. Watch the full interview on Erin Burnett OutFront. #CNN #News
Breakthrough GLP-1 implant promises major weight-loss benefits for pets
The world’s first GLP-1 weight loss treatment is being administered for pets on an experimental basis. The first cat was successfully dosed in the MEOW-1 study of OKV-119 – an investigational “ultra-long acting” GLP-1 implant, which, according to a press release, is being developed for weight management in cats. OKAVA Pharmaceuticals, the San Francisco-based manufacturer […]
Target beefs up protein, supplement offerings, capitalizing on weight loss drug trend
The rapid adoption of GLP-1 weight loss medications — drugs like Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Zepbound and Mounjaro — is reshaping how Americans eat and shop. It’s also changing how major corporations do business. From new product lines to expanding certain categories, companies are trying to capitalize on the lifestyle shifts […]
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly’s oral GLP-1, orforglipron Company plans to create 3,450 manufacturing and construction jobs at Lilly’s ninth U.S. manufacturing site announced since 2020 INDIANAPOLIS, Dec….
Weight loss drugs fill a gap for women with hormonal disorder PCOS | REUTERS
Many women with PCOS say they struggled for years to get a diagnosis and effective treatment. Now, more are finding relief as GLP-1 prescriptions for PCOS rose over sevenfold in the US since 2021. #pcos #glp1 #novonordisk #elililly #hormonaldisorder #News #Reuters #Newsfeed Read the story here: https://reut.rs/4rGTKhD 👉 Subscribe: http://smarturl.it/reuterssubscribe Keep up with the latest […]